公开(公告)号：US20250025499A1

公开(公告)日：2025-01-23

申请号：US18707096

申请日：2022-11-01

Applicant: FRED HUTCHINSON CANCER CENTER

Inventor： Marie BLEAKLEY ,  Melinda BIERNACKI

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  C12N5/0783 ,  C12N9/22 ,  C12N15/86

Abstract: Provided are compositions and methods of T cell-based immunotherapies targeting hematologic malignancies that contain a mutation in the SF3BI protein.

公开(公告)号：US20240409996A1

公开(公告)日：2024-12-12

申请号：US18619081

申请日：2024-03-27

Applicant: Fred Hutchinson Cancer Center

Inventor： Jason H. BIELAS

IPC: C12Q1/6874 ,  C12N15/10 ,  C12N15/70 ,  C12N15/81 ,  C12N15/85 ,  C12Q1/6827 ,  C12Q1/6869 ,  C40B40/08 ,  C40B50/06

Abstract: The present disclosure provides compositions and methods for accurately detecting mutations by uniquely tagging double stranded nucleic acid molecules with dual cyphers such that sequence data obtained from a sense strand can be linked to sequence data obtained from an anti-sense strand when sequenced, for example, by massively parallel sequencing methods.

公开(公告)号：US20240400651A1

公开(公告)日：2024-12-05

申请号：US18259748

申请日：2021-12-22

Applicant: VAL-CHUM, LIMITED PARTNERSHIP ,  FRED HUTCHINSON CANCER CENTER

Inventor： Leonidas STAMATATOS ,  Andrew MCGUIRE ,  Marie PANCERA ,  Andrés FINZI

IPC: C07K16/10 ,  A61K39/00 ,  A61P31/14

Abstract: The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.

公开(公告)号：US20240390491A1

公开(公告)日：2024-11-28

申请号：US18433277

申请日：2024-02-05

Applicant: Fred Hutchinson Cancer Center ,  Seattle Children's Hospital, dba Seattle Children's Research Institute

Inventor： Michael C. Jensen ,  Stanley R. Riddell ,  Michael Hudecek

IPC: A61K39/00 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C07K16/28 ,  C07K16/32 ,  C07K16/40

Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.

公开(公告)号：US12152252B2

公开(公告)日：2024-11-26

申请号：US16480273

申请日：2018-01-23

Applicant: Fred Hutchinson Cancer Center

Inventor： Martin Prlic ,  Julia Berkson ,  Chloe Slichter

IPC: C12Q1/68 ,  C12N5/0783 ,  C12Q1/6876 ,  G01N33/68

Abstract: Systems and methods to modulate the function of mucosal-associated invariant T (MAIT) cells in the absence of a T cell receptor (TCR) signal are described. The systems and methods can be used to elucidate the function of MAIT cells to assess potential therapeutic strategies for conditions associated with inflammation.

公开(公告)号：US20240226257A9

公开(公告)日：2024-07-11

申请号：US18492705

申请日：2023-10-23

Applicant: Fred Hutchinson Cancer Center ,  University of Washington

Inventor： Justin J. Taylor ,  Denise Galloway ,  Paul Nghiem ,  David Koelle ,  Haroldo Rodriguez ,  Joseph Carter

IPC: A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  G01N33/533 ,  G01N33/574

CPC classification number: A61K39/001111 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2809 ,  G01N33/533 ,  G01N33/57492 ,  A61K2039/53 ,  G01N2333/7051

Abstract: Antibodies that bind the tumor (T) antigen of the Merkel cell polyomavirus are disclosed. The antibodies can be use used in cell-based immunotherapies, antibody-based therapies, diagnostics, and detection assays, among other uses. Related diagnostics are also described

公开(公告)号：US20240150444A1

公开(公告)日：2024-05-09

申请号：US18548017

申请日：2022-02-25

Applicant: Fred Hutchinson Cancer Center

Inventor： Justin J. Taylor ,  Jim Boonyaratanakornkit

IPC: C07K16/10 ,  A61P31/12

CPC classification number: C07K16/1027 ,  A61P31/12 ,  A61K38/00 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76

Abstract: Antibodies that protect against respiratory viral infections including human parainfluenza viruses (HPIV), respiratory syncytial virus (RSV), and human metapneumovirus (HMPV) are described. Certain antibodies disclosed herein neutralize more than one virus (e.g., RSV and HMPV). The binding fragments of the antibodies can be engineered into numerous formats including those that provide simultaneous protection against multiple viruses.

公开(公告)号：US20240094209A1

公开(公告)日：2024-03-21

申请号：US18509663

申请日：2023-11-15

Applicant: Fred Hutchinson Cancer Center

Inventor： Evan Greene ,  Greg Finak ,  Raphael Gottardo

IPC: G01N33/574 ,  G16B5/00 ,  G16B25/10

CPC classification number: G01N33/5743 ,  G16B5/00 ,  G16B25/10

Abstract: Disclosed herein are to markers, methods and systems for identifying cell populations, diagnosing, monitoring and treating cancer, including biomarkers predictive of response to immunotherapy treatment in Merkel cell carcinoma.

公开(公告)号：US11932691B2

公开(公告)日：2024-03-19

申请号：US17157810

申请日：2021-01-25

Applicant: Fred Hutchinson Cancer Center

Inventor： Ashwini Balakrishnan ,  Benjamin G. Hoffstrom ,  Julie Randolph-Habecker ,  Stanley R. Riddell

IPC: C07K16/28 ,  G01N33/574

CPC classification number: C07K16/2803 ,  G01N33/57492 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/92 ,  G01N2333/70503

Abstract: The present disclosure relates to anti-ROR1 binding proteins, including those that bind to a ROR1 or portion thereof such as an intracellular C terminal portion of a ROR1 protein, and the use of such binding proteins in immunohistochemical and diagnostic methods. Related kits and methods of using the binding proteins are also provided, as are methods of treatment of subjects having diseases or conditions determined to be candidates for such treatments by the binding proteins or methods of this disclosure.

公开(公告)号：US11872195B2

公开(公告)日：2024-01-16

申请号：US16222942

申请日：2018-12-17

Applicant: FRED HUTCHINSON CANCER CENTER

Inventor： Matthias Stephan ,  Howell F. Moffett

IPC: A61K48/00 ,  C12N9/22 ,  C07K14/705 ,  C12N15/88 ,  A61K35/14

CPC classification number: A61K48/005 ,  C07K14/705 ,  C12N9/22 ,  C12N15/88 ,  A61K35/14

Abstract: Compositions and methods that rapidly and selectively modify hematopoietic stem cells (or cells derived therefrom) to achieve therapeutic objectives by providing for transient expression of nucleic acids are described. The transient expression leads to permanent therapeutic changes in the modified cells, referred to herein as “hit and run” effects.